News

Angelini Ventures Invests in Therini Bio's Innovative Future

Angelini Ventures Invests in Therini Bio's Innovative Future

Angelini Ventures Participates in Therini Bio’s Funding

In a significant move for the biotech industry, Angelini Ventures proudly announces its investment in a $39 million extension of the Series A financing round for Therini Bio. This U.S.-based clinical biotech company specializes in developing innovative fibrin-targeting immunotherapies aimed at treating neurodegenerative diseases characterized by vascular dysfunction.

Investment Highlights and Collaborating Partners

Angelini Ventures joins a notable consortium of international healthcare investors that includes Apollo Health Ventures, SV Health Investors’ Biotech Fund, the Dementia Discovery Fund, and Eli Lilly among others. This infusion of funds brings Therini Bio's total financing from the Series A round to an impressive $75 million, indicating strong confidence in the company's mission and potential impact.

Focus on Advancing Clinical Research

The investment provides critical support for Therini Bio's Phase 1b studies, aiming to evaluate its promising candidate, THN391. Designed as a first-in-class monoclonal antibody, THN391 holds potential in selectively averting fibrin-mediated neuroinflammation, addressing pressing conditions such as Alzheimer’s Disease and Diabetic Macular Edema.

The Vision Behind the Investment

Dr. Thomas Thestrup, Senior Principal at Angelini Ventures, expressed enthusiasm about supporting Therini Bio's pioneering approach. He remarked, “We are eager to enhance the fight against neurodegenerative diseases by targeting their underlying inflammatory drivers. Therini Bio's development of a selective antibody therapy targeting fibrin-mediated inflammation shows great promise for Alzheimer’s and other CNS disorders.”

New Board Presence and Strategic Oversight

As part of this partnership, Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will take on the role of Board Observer at Therini Bio. This strategic involvement indicates Angelini Ventures' commitment to ensuring effective governance and guidance as Therini progresses through its clinical phases.

Advancing Towards Innovative Therapeutics

Dr. Tara Nickerson, the Chief Executive Officer of Therini Bio, articulated gratitude for the backing of such a prestigious investment group. She noted that their collaboration would help propel the advancement of THN391 through clinical trials, bringing hope for effective treatments against debilitating conditions like Alzheimer’s and Diabetic Macular Edema.

About Angelini Ventures

Angelini Ventures serves as the venture capital branch of Angelini Industries, focused on investing in transformative innovations in the BioTech and Digital Health fields. The firm plans to invest €300 million globally, leveraging a diverse team of advisors and partners to accelerate growth in biotech companies.

About Angelini Industries

Founded in 1919, Angelini Industries has evolved into a multinational group that employs around 5,800 individuals across 21 different countries, generating over two billion euros in revenue. Their strategic investments and a strong emphasis on research and development make them a key player within the sectors they operate in.

About Therini Bio

Therini Bio is a forward-thinking clinical-stage biotech company dedicated to developing immunotherapies that target neuroinflammation caused by vascular dysfunction. The company's innovative therapies are aimed at conditions such as Alzheimer’s disease and Diabetic Macular Edema, where reducing neuroinflammation is crucial to improving patient outcomes. Their extensive network of investors reflects confidence in their vision to transform treatment options.

Frequently Asked Questions

What is the purpose of Angelini Ventures' investment in Therini Bio?

The investment aims to support Therini Bio's clinical trials evaluating their innovative therapies for neurodegenerative diseases.

What specific therapies is Therini Bio developing?

Therini Bio is developing immunotherapies that target fibrin-mediated neuroinflammation, particularly for Alzheimer's disease and Diabetic Macular Edema.

Who are the notable investors alongside Angelini Ventures?

Investors alongside Angelini Ventures include Apollo Health Ventures, SV Health Investors, Eli Lilly, among others.

What role does Fabrizio Calisti have in Therini Bio?

Fabrizio Calisti will serve as a Board Observer for Therini Bio, ensuring strategic oversight of their clinical efforts.

What is the long-term vision of Angelini Ventures?

Angelini Ventures aims to invest in disruptive innovations in healthcare sectors, supporting growth in transformative biotech companies globally.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 5

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Micro Irrigation Systems: The Future of Sustainable Farming

Updated Category News Views 184

Micro Irrigation Systems: Transforming Global Agriculture The micro irrigation systems market is poised for remarkable growth, expected to expand significantly due to the increasing demand for sustainable agricultural practices. These systems are projected to elevate market valuation from USD 10.9 billion to USD 27.4 billion over the next decade, exhibiting a strong CAGR...

Continue Reading
Empowering Communities: Diaspora Groceries Supplier Summit Launch

Updated Category News Views 276

Empowering Communities: Diaspora Groceries Supplier Summit Launch Diaspora Groceries is thrilled to announce its inaugural Diaspora Diversity Supplier Summit, in partnership with its newly established nonprofit arm, Diaspora Groceries Cares. Taking place over two transformative days, the summit invites food suppliers, farmers, and advocates to gather for insightful...

Continue Reading
EMP Metals Unveils Enhanced Resource Estimate for Lithium Projects

Updated Category News Views 95

EMP Metals Reports Updated Resource Estimate EMP Metals Corp. (CSE: EMPS, OTCQB: EMPPF) is thrilled to share an updated Technical Report detailing the resource estimates for its Viewfield and Mansur lithium brine projects. This comprehensive report showcases a remarkable increase in the total resource, significantly boosting both the indicated and inferred lithium...

Continue Reading
Exploring the Impact of Google Cloud in Enterprise Solutions

Updated Category News Views 264

ISG Evaluates Google Cloud Partner Ecosystem Information Services Group (ISG) (Nasdaq: III), a prominent global technology research and advisory firm, is embarking on an in-depth research study that will gauge the effectiveness of service providers in supporting enterprises using the Google Cloud Platform (GCP) for artificial intelligence (AI) and various other workloads....

Continue Reading
HiRO Joins Forces with CHA University for Future of Health

Updated Category News Views 294

HiRO Collaborates with CHA University Bundang Medical Center Harvest Integrated Research Organization (HiRO), a distinguished global clinical research organization (CRO), has recently entered into a strategic partnership with CHA University Bundang Medical Center (CBMC), a highly respected medical institution in South Korea. This collaboration promises to strengthen the...

Continue Reading